These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 19135616

  • 21. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
    Funder JW.
    Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
    [Abstract] [Full Text] [Related]

  • 22. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M, Fujita T.
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [Abstract] [Full Text] [Related]

  • 23. Primary aldosteronism.
    Carey RM.
    Horm Res; 2009 Jan; 71 Suppl 1():8-12. PubMed ID: 19153497
    [Abstract] [Full Text] [Related]

  • 24. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
    Horký K.
    Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Primary aldosteronism and metabolic syndrome.
    Fallo F, Pilon C, Urbanet R.
    Horm Metab Res; 2012 Mar; 44(3):208-14. PubMed ID: 22116746
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Aldosterone and the heart: from basic research to clinical evidence.
    Catena C, Colussi G, Marzano L, Sechi LA.
    Horm Metab Res; 2012 Mar; 44(3):181-7. PubMed ID: 22095099
    [Abstract] [Full Text] [Related]

  • 31. [Aldosterone blockade in essential hypertension].
    Venco A, Grandi AM.
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [Abstract] [Full Text] [Related]

  • 32. Aldosterone and end-organ damage.
    Marney AM, Brown NJ.
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [Abstract] [Full Text] [Related]

  • 33. Comorbidities in primary aldosteronism.
    Quinkler M, Born-Frontsberg E, Fourkiotis VG.
    Horm Metab Res; 2010 Jun; 42(6):429-34. PubMed ID: 20049673
    [Abstract] [Full Text] [Related]

  • 34. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma.
    TAIPAI Study GroupDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH, Hung KY, Kao TW, Lin SL, Yen RF, Chen YM, Hsieh BS, Wu KD.
    Am J Kidney Dis; 2009 Oct; 54(4):665-73. PubMed ID: 19628318
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Neurohormones and heart failure: the importance of aldosterone.
    Odedra K, Ferro A.
    Int J Clin Pract; 2006 Jul; 60(7):835-46. PubMed ID: 16846401
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW.
    Prog Cardiovasc Dis; 2010 Jul; 52(5):393-400. PubMed ID: 20226957
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.